Schedule of Segment Reporting Information, by Segment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biopharmaceuticals |
|
Bioprocessing |
|
|
|
|
Three Months Ended December 31, 2021 (in thousands) |
|
iBio, Inc. |
|
iBio CDMO |
|
Eliminations |
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues - external customers |
|
$ |
— |
|
$ |
168 |
|
$ |
— |
|
$ |
168 |
Revenues - intersegment |
|
|
94 |
|
|
430 |
|
|
(524) |
|
|
— |
Cost of goods sold |
|
|
— |
|
|
113 |
|
|
— |
|
|
113 |
Gross profit |
|
|
94 |
|
|
485 |
|
|
(524) |
|
|
55 |
Research and development |
|
|
2,213 |
|
|
1,549 |
|
|
(431) |
|
|
3,331 |
General and administrative |
|
|
4,832 |
|
|
3,623 |
|
|
(93) |
|
|
8,362 |
Operating loss |
|
|
(6,950) |
|
|
(4,688) |
|
|
— |
|
|
(11,638) |
Interest expense |
|
|
— |
|
|
(328) |
|
|
— |
|
|
(328) |
Interest and other income |
|
|
41 |
|
|
5 |
|
|
— |
|
|
46 |
Consolidated net loss |
|
|
(6,909) |
|
|
(5,011) |
|
|
— |
|
|
(11,920) |
Total assets |
|
|
172,004 |
|
|
37,633 |
|
|
(83,189) |
|
|
126,448 |
Finance lease ROU assets |
|
|
— |
|
|
109 |
|
|
— |
|
|
109 |
Operating lease ROU assets |
|
|
3,334 |
|
|
1,957 |
|
|
— |
|
|
5,291 |
Fixed assets, net |
|
|
600 |
|
|
32,281 |
|
|
— |
|
|
32,881 |
Intangible assets, net |
|
|
5,041 |
|
|
— |
|
|
— |
|
|
5,041 |
Amortization of ROU assets |
|
|
— |
|
|
147 |
|
|
— |
|
|
147 |
Depreciation expense |
|
|
— |
|
|
517 |
|
|
— |
|
|
517 |
Amortization of intangible assets |
|
|
123 |
|
|
— |
|
|
— |
|
|
123 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biopharmaceuticals |
|
Bioprocessing |
|
|
|
|
Three Months Ended December 31, 2020 (in thousands) |
|
iBio, Inc. |
|
iBio CDMO |
|
Eliminations |
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues - external customers |
|
$ |
190 |
|
$ |
515 |
|
$ |
— |
|
$ |
705 |
Revenues - intersegment |
|
|
238 |
|
|
288 |
|
|
(526) |
|
|
— |
Cost of goods sold |
|
|
215 |
|
|
(4) |
|
|
— |
|
|
211 |
Gross profit |
|
|
213 |
|
|
807 |
|
|
(526) |
|
|
494 |
Research and development |
|
|
373 |
|
|
2,302 |
|
|
(301) |
|
|
2,374 |
General and administrative |
|
|
2,971 |
|
|
2,919 |
|
|
(225) |
|
|
5,665 |
Operating loss |
|
|
(3,131) |
|
|
(4,414) |
|
|
— |
|
|
(7,545) |
Interest expense |
|
|
— |
|
|
(615) |
|
|
— |
|
|
(615) |
Interest and other income |
|
|
29 |
|
|
— |
|
|
— |
|
|
29 |
Consolidated net loss |
|
|
(3,102) |
|
|
(5,029) |
|
|
— |
|
|
(8,131) |
Total assets |
|
|
163,991 |
|
|
33,789 |
|
|
(52,374) |
|
|
145,406 |
Finance lease ROU assets |
|
|
— |
|
|
26,786 |
|
|
— |
|
|
26,786 |
Fixed assets, net |
|
|
— |
|
|
5,010 |
|
|
— |
|
|
5,010 |
Intangible assets, net |
|
|
1,185 |
|
|
— |
|
|
— |
|
|
1,185 |
Amortization of ROU assets |
|
|
— |
|
|
415 |
|
|
— |
|
|
415 |
Depreciation expense |
|
|
— |
|
|
114 |
|
|
— |
|
|
114 |
Amortization of intangible assets |
|
|
73 |
|
|
— |
|
|
— |
|
|
73 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biopharmaceuticals |
|
Bioprocessing |
|
|
|
|
Six Months Ended December 31, 2021 (in thousands) |
|
(iBio, Inc.) |
|
(iBio CDMO) |
|
Eliminations |
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues - external customers |
|
$ |
84 |
|
$ |
295 |
|
$ |
— |
|
$ |
379 |
Revenues - intersegment |
|
|
176 |
|
|
885 |
|
|
(1,061) |
|
|
— |
Cost of goods sold |
|
|
— |
|
|
153 |
|
|
— |
|
|
153 |
Gross profit |
|
|
260 |
|
|
1,027 |
|
|
(1,061) |
|
|
226 |
Research and development |
|
|
3,734 |
|
|
3,016 |
|
|
(908) |
|
|
5,842 |
General and administrative |
|
|
8,316 |
|
|
6,833 |
|
|
(153) |
|
|
14,996 |
Operating loss |
|
|
(11,789) |
|
|
(8,823) |
|
|
— |
|
|
(20,612) |
Interest expense |
|
|
— |
|
|
(937) |
|
|
— |
|
|
(937) |
Forgiveness of note payable and accrued interest |
|
|
— |
|
|
607 |
|
|
— |
|
|
607 |
Interest and other income |
|
|
77 |
|
|
5 |
|
|
— |
|
|
82 |
Consolidated net loss |
|
|
(11,712) |
|
|
(9,148) |
|
|
— |
|
|
(20,860) |
Total assets |
|
|
172,004 |
|
|
37,633 |
|
|
(83,189) |
|
|
126,448 |
Finance lease ROU assets |
|
|
— |
|
|
109 |
|
|
— |
|
|
109 |
Operating lease ROU assets |
|
|
3,334 |
|
|
1,957 |
|
|
— |
|
|
5,291 |
Fixed assets, net |
|
|
600 |
|
|
32,281 |
|
|
— |
|
|
32,881 |
Intangible assets, net |
|
|
5,041 |
|
|
— |
|
|
— |
|
|
5,041 |
Amortization of ROU assets |
|
|
— |
|
|
563 |
|
|
— |
|
|
563 |
Depreciation expense |
|
|
— |
|
|
823 |
|
|
— |
|
|
823 |
Amortization of intangible assets |
|
|
211 |
|
|
— |
|
|
— |
|
|
211 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biopharmaceuticals |
|
Bioprocessing |
|
|
|
|
Six Months Ended December 31, 2020 (in thousands) |
|
(iBio, Inc.) |
|
(iBio CDMO) |
|
Eliminations |
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues - external customers |
|
$ |
397 |
|
$ |
718 |
|
$ |
— |
|
$ |
1,115 |
Revenues - intersegment |
|
|
476 |
|
|
498 |
|
|
(974) |
|
|
— |
Cost of goods sold |
|
|
269 |
|
|
49 |
|
|
— |
|
|
318 |
Gross profit |
|
|
604 |
|
|
1,167 |
|
|
(974) |
|
|
797 |
Research and development |
|
|
608 |
|
|
4,147 |
|
|
(519) |
|
|
4,236 |
General and administrative |
|
|
5,643 |
|
|
5,842 |
|
|
(455) |
|
|
11,030 |
Operating loss |
|
|
(5,647) |
|
|
(8,822) |
|
|
— |
|
|
(14,469) |
Interest expense |
|
|
— |
|
|
(1,229) |
|
|
— |
|
|
(1,229) |
Interest and other income |
|
|
32 |
|
|
1 |
|
|
— |
|
|
33 |
Consolidated net loss |
|
|
(5,615) |
|
|
(10,050) |
|
|
— |
|
|
(15,665) |
Total assets |
|
|
163,991 |
|
|
33,789 |
|
|
(52,374) |
|
|
145,406 |
Finance lease ROU assets |
|
|
— |
|
|
26,786 |
|
|
— |
|
|
26,786 |
Fixed assets, net |
|
|
— |
|
|
5,010 |
|
|
— |
|
|
5,010 |
Intangible assets, net |
|
|
1,185 |
|
|
— |
|
|
— |
|
|
1,185 |
Amortization of ROU assets |
|
|
— |
|
|
830 |
|
|
— |
|
|
830 |
Depreciation expense |
|
|
— |
|
|
211 |
|
|
— |
|
|
211 |
Amortization of intangible assets |
|
|
145 |
|
|
— |
|
|
— |
|
|
145 |
|